Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Severe cutaneous adverse reactions and burn-centre care

Dermatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Painful skin or mucosal loss

Skin pain, dusky atypical targets, blisters, detachment or erosions at mouth, eyes or genital mucosa after a medicine can herald SJS/TEN; shock, hypoxia, oliguria, confusion or rapidly rising organ tests signals acute skin and multiorgan failure.

Action: Stop suspected culprit medicine immediately, assess ABCDE and airway, obtain urgent dermatology and critical-care review, discuss rapid transfer to an age-appropriate Burns Centre or specialised dermatology centre co-located with intensive care, and begin warm, gentle, non-adhesive supportive care without waiting for biopsy.

Synopsis

Recognise SJS/TEN, DRESS and AGEP early, stop the most likely culprit safely, distinguish epidermal loss from mimics, and deliver multidisciplinary skin-failure, mucosal, ocular and organ care through the appropriate specialist centre.

  • SJS/TEN typically causes prodrome, disproportionate skin pain, dusky macules or atypical targets, flaccid blisters, epidermal detachment and prominent ocular, oral or genital erosions.
  • Classify by detached or detachable surface: SJS below 10%, overlap 10% to 30%, and TEN above 30%; extent can evolve after presentation and must be remapped.
  • DRESS usually emerges two to eight weeks after starting a culprit with fever, widespread eruption, facial oedema, nodes, eosinophilia or atypical lymphocytes and liver, kidney, lung or cardiac injury.
  • Build a calendar of every medicine started, increased, intermittently taken or stopped in the previous two months, including antimicrobials, anticonvulsants, allopurinol, analgesics and non-prescription products.
  • Withdraw likely culprit treatment immediately but do not create avoidable harm by indiscriminately stopping physiological corticosteroid, antiseizure cover or another essential medicine without a safe substitute.
  • SJS/TEN care prioritises culprit withdrawal and meticulous multidisciplinary support; no single systemic immunomodulator has conclusive superiority over high-quality conservative care in the UK guideline.
  • Early ophthalmology, daily eye, mouth and urogenital review, respiratory surveillance, individualised fluids, enteral nutrition, pain control and non-traumatic wound care prevent lifelong disability as well as death.
  • Do not give routine prophylactic systemic antibiotics; culture strategically and treat clinical infection, because indiscriminate exposure selects Candida and resistant colonisation.
  • Document the exact culprit and drugs to avoid, notify every care setting and report through MHRA Yellow Card; specialist allergy input is needed when causality remains uncertain or broad avoidance compromises care.

Key red flags

Skin pain, epidermal tenderness, dusky or blistering targets, positive shearing, any mucosal erosion, facial oedema with fever, eosinophilia or organ injury, pustules with systemic illness, hypotension, hypoxia, oliguria, confusion, rising transaminases, myocarditis symptoms or a rapidly spreading eruption requires same-day hospital and dermatology assessment.

Acute skin failure

Hypothermia, tachycardia, hypotension, oliguria, confusion, severe pain, expanding detachment or hypoxia indicates barrier and organ failure regardless of the named SCAR.

Investigation priorities

01
Medicine chronology and causality assessmentFirst step

Identify the likely culprit quickly enough to reduce ongoing injury.

Management branches

First-line emergency sequenceStop culprit and transfer early

Painful blistering, epidermal loss or severe mucositis raises SJS/TEN or another SCAR.

  1. Stop the likely culprit immediately, preserve essential treatment with safe alternatives, assess ABCDE and airway, weigh the patient and map skin and every mucosal site.
  2. Contact dermatology, critical care and the regional specialised service early; arrange care in an age-specific Burns Centre or dermatology centre co-located with intensive care.
  3. Obtain histology and immunofluorescence biopsies, FBC, metabolic and organ profiles, cultures and imaging without delaying transfer or supportive treatment.
  4. Calculate SCORTEN within 24 hours, record causality reasoning and notify ophthalmology immediately so the first formal eye examination occurs within 24 hours.

Key medicines

White soft paraffin and liquid paraffin 50:50 ointmentApply gently over intact and denuded epidermis after warmed cleansing and whenever the surface dries, generally at least every 4 hours during acute specialist care.Application can shear fragile epidermis, so use experienced nursing or aerosolised delivery when appropriate; paraffin-contaminated linen and dressings are a major fire hazard and require strict flame avoidance.
Weight-adjusted LMWH thromboprophylaxisGive the hospital protocol's prophylactic subcutaneous dose once daily, adjusted for body weight and renal function, while mobility is substantially reduced unless contraindicated.Review active bleeding, severe thrombocytopenia, renal impairment and imminent procedures each day; extensive skin loss changes injection-site choice, and therapeutic anticoagulation requires a separate indication.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • PubMed record for UK adult SJS TEN guidelineCulprit withdrawal, SCORTEN, specialist setting, fluids, wounds, infection, eye and mucosal care, active-therapy uncertainty and follow-up.
  • BAD SJS TEN patient leafletCurrent patient-facing recognition, causes, hospital treatment and long-term medicine avoidance.
  • BAD highly specialised service specificationAge-specific Burns Centre or specialised dermatology centre co-located with intensive-care requirement for SJS/TEN.
  • NICE drug allergy recommendationsRecognition of SJS/TEN, DRESS and AGEP, structured documentation, information sharing and specialist referral.
  • MHRA Yellow Card schemeNational reporting route for suspected serious adverse drug reactions and device incidents.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom